From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done
Shares of Moderna (MRNA) extended a two-month surge on Thursday, helped most recently by CEO Stéphane Bancel’s optimism about the company’s potential outside of COVID vaccines and backed by positive late-stage trial results for the company’s cancer vaccine announced last month.From about $63 on Aug…